Atlas Trials

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Clinical trial NCT02294357 · TERMINATED

Trial details

NCT number
NCT02294357
Sponsor
Oncotherapeutics
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2014-12-01
Primary completion
2020-09-21
Enrollment
45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.